Table of Contents
ISRN Spectroscopy
Volume 2012, Article ID 659257, 9 pages
http://dx.doi.org/10.5402/2012/659257
Research Article

Method Development and Validation of Darifenacin in Rat Plasma by Liquid Chromatography-Tandem Mass Spectrometry: Application to a Pharmacokinetic Study

1Pacific University of Higher Education and Research, Udaipur, Rajasthan 313001, India
2Department of Pharmaceutical Chemistry, Nirmala College of Pharmacy, Madras Road, Kadapa 516002, Andhra Pradesh, India

Received 12 August 2012; Accepted 4 October 2012

Academic Editors: F.-F. Hsu, E. Saint-Aman, and E. Stathatos

Copyright © 2012 Thejomoorthy Karavadi and B. R. Challa. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Tomillero and M. A. Moral, “Gateways to clinical trials,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 32, no. 10, pp. 749–773, 2010. View at Google Scholar · View at Scopus
  2. A. Skerjanec, “The clinical pharmacokinetics of darifenacin,” Clinical Pharmacokinetics, vol. 45, no. 4, pp. 325–350, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. K. C. Beaumont, N. J. Cussans, D. J. Nichols, and D. A. Smith, “Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man,” Xenobiotica, vol. 28, no. 1, pp. 63–75, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Hill, M. Elhilali, R. J. Millard et al., “Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study,” Current Medical Research and Opinion, vol. 23, no. 11, pp. 2697–2704, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Kerbusch, P. A. Milligan, and M. O. Karlsson, “Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data,” British Journal of Clinical Pharmacology, vol. 57, no. 2, pp. 170–180, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Sridharan, U. A. Thenmozhi, L. P. Kumar, A. D. Chintalapati, M. V. Ramanaiah, and Y. Phanikishore, “Development and validation of UV spectrophotometric method of darifenacin hydrobromide in bulk and tablet dosage form,” Asian Journal of Pharmaceutical Analysis, vol. 1, no. 3, pp. 43–45, 2011. View at Google Scholar
  7. P. S. Sai Praveen, V. Jagathi, G. Devala Rao, and G. Sudhakar Saibabu, “Visible spectrophotometric methods for the determination of darifenacin,” Research Journal of Pharmaceutical, Biological and Chemical Sciences, vol. 1, no. 2, pp. 254–257, 2010. View at Google Scholar · View at Scopus
  8. P. Sai Praveen, M. Shaiba, A. Swetha, A. Aruna Jyothi, and A. Nishat, “Spectrophotometric methods for the determination of darifenacin,” Research Journal of Pharmaceutical, Biological and Chemical Sciences, vol. 1, no. 4, pp. 350–353, 2010. View at Google Scholar · View at Scopus
  9. P. Sai Praveen, G. Devala Rao, V. Jagathi, M. Shaiba, and C. H. Manohar Babu, “Spectroflourimetric method for the estimation of darifenacin in pure and pharmaceutical formulations,” Asian Journal of Pharmaceutical and Clinical Research, vol. 4, no. 1, pp. 44–46, 2011. View at Google Scholar · View at Scopus
  10. S. Kathirvel, S. V. Satyanarayana, and G. Devalarao, “Densitometric evaluation of stability—indicating HPTLC Method for the analysis of darifenacin hydrobromide in bulk and in tablet dosage form,” Journal of Liquid Chromatography and Related Technologies, vol. 35, no. 2, pp. 280–293, 2012. View at Publisher · View at Google Scholar
  11. V. Rajesh, K. Rajendra Prasad, A. Suneetha, and S. Kathirvel, “Development and validation of Rp-Hplc method for estimation of darifenacin hydrobromide in bulk and tablet dosage form,” Asian Journal of Research in Chemistry, vol. 4, no. 6, 2011. View at Google Scholar
  12. P. Radhakrishnanand, D. V. Subba Rao, and V. Himabindu, “A validated LC method for determination of the enantiomeric purity of darifenacin in bulk drug and extended release tablets,” Chromatographia, vol. 68, no. 11-12, pp. 1059–1062, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Z. Meneghini, C. Junqueira, S. A. Andrade et al., “Chemometric evaluation of darifenacin hydrobromide using a stability-indicating reversed-phase LC method,” Journal of Liquid Chromatography and Related Technologies, vol. 34, no. 18, pp. 2169–2184, 2011. View at Publisher · View at Google Scholar
  14. A. Thenmozhi, Umarani, and D. Sridharan, “A stability indicating HPLC method for the estimation of darifenacin hydrobromide in pure and tablet dosage form,” Asian Journal of Biochemical and Pharmaceutical Research, vol. 3, no. 1, pp. 48–61, 2011. View at Google Scholar
  15. S. Thomas, S. K. Paul, S. Shandilya et al., “Identification and structural elucidation of two process impurities and stress degradants in darifenacin hydrobromide active pharmaceutical ingredient by LC-ESI/MSn,” Analyst, vol. 137, no. 15, pp. 3571–3582, 2012. View at Publisher · View at Google Scholar
  16. A. Yoshida, S. Maruyama, D. Fukumoto, H. Tsukada, Y. Ito, and S. Yamada, “Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography,” Life Sciences, vol. 87, no. 5-6, pp. 175–180, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Maruyama, H. Tsukada, S. Nishiyama et al., “In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment,” Journal of Pharmacology and Experimental Therapeutics, vol. 325, no. 3, pp. 774–781, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Ito, L. Oyunzul, M. Seki, T. Fujino, M. Matsui, and S. Yamada, “Quantitative analysis of the loss of muscarinic receptors in various peripheral tissues in M1-M5 receptor single knockout mice,” British Journal of Pharmacology, vol. 156, no. 7, pp. 1147–1153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Masuda, N. Kanayama, S. Manita, S. Ohmori, and T. Ooie, “Development and validation of bioanalytical methods for Imidafenacin (KRP-197/ONO-8025) and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry,” Journal of Chromatography B, vol. 853, no. 1-2, pp. 70–79, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Kaye, W. J. Herron, P. V. Macrae et al., “Rapid, solid phase extraction technique for the high-throughput assay of darifenacin in human plasma,” Analytical Chemistry, vol. 68, no. 9, pp. 1658–1660, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. Center for Biologics Evaluation and Research (CBER), Guidance for Industry: Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2001.
  22. Centre for Drug Evaluation and Research (CDER), Guidance for Industry Food- Effect Bio Availability and Fed Bio Equivalence Studies, U.S. Department of Health and Human services Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), 2002.